23 June 2026 in International Journal of Gynecology & Obstetrics
IVIsabel Pinto Amorim das Virgens
Isabel Pinto Amorim das Virgens
+3
Background: Pre‐eclampsia is a serious pregnancy‐related syndrome lacking accurate prognostic markers. MicroRNA‐210, overexpressed in the circulation of women with pre‐eclampsia, has recently emerged as a promising biomarker. Objectives: We conducted a systematic review and meta‐analysis to evaluate the relationship between miR‐210 levels and pre‐eclampsia at different degrees of severity. Search Strategy: The study was prospectively registered on PROSPERO (CRD42024604698) and included a comprehensive systematic search of five databases conducted on November 21, 2024. Selection Criteria, Data Collection and Analysis: The included studies involved pregnant women with mild or severe pre‐eclampsia compared to normotensive controls, meeting guideline‐based diagnostic criteria and reporting circulating microRNA‐210. Precalculated effect sizes were pooled to obtain a weighted mean and 95% confidence interval (CI) for microRNA‐210‐fold increase. Subgroup analysis assessed pre‐eclampsia severity, using an inverse variance method in random‐effects meta‐analysis models. Main Results: Our search identified 776 records, of which seven were deemed eligible for analysis. The fold change values, reflecting the increase in microRNA‐210 levels between the control and pre‐eclamptic populations, were 3.33 (CI: 0.69–5.98; I 2 = 93%, CI: 88–96%) in the mild pre‐eclampsia group and 7.23 (CI: 2.27–12.18; I 2 = 98%, CI: 98–99%) in the severe pre‐eclampsia group, indicating a significant effect ( P = 0.01) in the subgroup difference tests. The mean ratio of microRNA‐210‐fold change between the two severity groups was 2.05 (CI: 1.41–2.69; I 2 = 85%, P < 0.01), favoring the severe population. Conclusion: Elevated microRNA‐210 levels are strongly associated with pre‐eclampsia severity at the time of diagnosis, with a consistent, significant stepwise increase from mild to severe disease. Whether miR‐210 holds predictive value earlier in pregnancy remains to be established in prospective studies with first‐trimester sampling.
15 September 2026 in International Journal of Gynecology & Obstetrics
IVIsabel Pinto Amorim das Virgens
Isabel Pinto Amorim das Virgens
+3
Click on the article title to read more.
7 February 2026 in European Journal of Surgical Oncology
Early-stage cervical cancer tumours ≥2 cm present a dilemma for fertility preservation, as guidelines generally discourage fertility-sparing surgery (FSS) due to oncologic risks. Neoadjuvant chemotherapy (NACT) followed by FSS has emerged as an alternative to downstage tumours. This study evaluated recurrence and pregnancy outcomes of NACT + FSS versus upfront FSS. A PROSPERO-registered (CRD42024605906) meta-analysis was conducted using PubMed, EMBASE, and Cochrane (updated Feb 26, 2025). Eligible studies included women with early-stage cervical cancer (FIGO 2018 IB2-IIA1; ≥2 cm) undergoing upfront FSS or NACT + FSS. Pooled proportions with 95% confidence intervals (CIs) were calculated using a random effects model. Nineteen observational studies (n = 1453) were analysed. Indirect comparison indicated significantly higher pooled pregnancy rate for NACT + FSS (31%; 95% CI: 23-41%) compared to upfront FSS (8%; CI: 1-43%; p = 0.002). Pooled recurrence rate was statistically similar: 10% (CI: 5-20%) for upfront FSS and 13% (CI: 9-20%) for NACT + FSS (p = 0.415). Studies generally exhibited a moderate-to-high risk of bias. NACT followed by FSS appears to enhance fertility outcomes without increasing oncologic risk compared to upfront FSS in patients with tumours ≥2 cm. These findings support the personalized extension of fertility-sparing indications, though prospective validation remains necessary.